AR085440A1 - Biomarcadores para predecir la recurrencia de metastasis de cancer colorrectal - Google Patents

Biomarcadores para predecir la recurrencia de metastasis de cancer colorrectal

Info

Publication number
AR085440A1
AR085440A1 ARP120100891A ARP120100891A AR085440A1 AR 085440 A1 AR085440 A1 AR 085440A1 AR P120100891 A ARP120100891 A AR P120100891A AR P120100891 A ARP120100891 A AR P120100891A AR 085440 A1 AR085440 A1 AR 085440A1
Authority
AR
Argentina
Prior art keywords
msi
patients
crc
biomarkers
recurrence
Prior art date
Application number
ARP120100891A
Other languages
English (en)
Inventor
Minoru Koi
C Richard Boland
Original Assignee
Baylor Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor Res Inst filed Critical Baylor Res Inst
Publication of AR085440A1 publication Critical patent/AR085440A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Biomarcadores y métodos para predecir la supervivencia sin recurrencia y determinar el riesgo de metástasis hepático (LM) colorrectal por determinación del nivel de inestabilidad de microsatélites en repeticiones de tetranucleótidos (EMAST) y en loci de repeticiones de mono- y un dinucleótido (MSI-L) o un SMARCA2R-LOH en pacientes con cáncer colorrectal (CRC). Los resultados obtenidos indican que los pacientes en etapa II y III con MSI-M tenían una supervivencia sin recurrencia más corto que el resto de los pacientes con niveles altos de MSI (MSI-H) o con microsatélites altamente estables, y que la MSI-M es un predictor independiente de la metástasis distante recurrente en el CRC en etapa II y III primario. Se observó que SMARCA2R-LOH y MSI-M están presentes en los tejidos de LM y CRC primario en etapa IV.
ARP120100891A 2011-03-18 2012-03-16 Biomarcadores para predecir la recurrencia de metastasis de cancer colorrectal AR085440A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161454107P 2011-03-18 2011-03-18
US201161549541P 2011-10-20 2011-10-20

Publications (1)

Publication Number Publication Date
AR085440A1 true AR085440A1 (es) 2013-10-02

Family

ID=46828933

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120100891A AR085440A1 (es) 2011-03-18 2012-03-16 Biomarcadores para predecir la recurrencia de metastasis de cancer colorrectal

Country Status (6)

Country Link
US (1) US20120238464A1 (es)
EP (1) EP2686450A4 (es)
AR (1) AR085440A1 (es)
CA (1) CA2830416A1 (es)
TW (1) TW201300777A (es)
WO (1) WO2012129092A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11913065B2 (en) 2012-09-04 2024-02-27 Guardent Health, Inc. Systems and methods to detect rare mutations and copy number variation
US10876152B2 (en) 2012-09-04 2020-12-29 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
WO2014039556A1 (en) 2012-09-04 2014-03-13 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US20160040229A1 (en) 2013-08-16 2016-02-11 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
EP3087204B1 (en) 2013-12-28 2018-02-14 Guardant Health, Inc. Methods and systems for detecting genetic variants
EP3390668A4 (en) 2015-12-17 2020-04-01 Guardant Health, Inc. METHODS OF DETERMINING THE NUMBER OF TUMOR GENE COPIES BY ACELLULAR DNA ANALYSIS
WO2019041689A1 (zh) * 2017-08-31 2019-03-07 立森印迹诊断技术（无锡）有限公司 用于结直肠肿瘤的印记基因分级模型及其组成的系统
CN108676888B (zh) * 2018-07-12 2022-01-28 吉林大学 一种肺部恶性肿瘤易感性预测试剂盒及系统
US20210189505A1 (en) * 2018-08-23 2021-06-24 Nantcell, Inc. Assessing microsatellite instability by liquid biopsy
WO2020081607A1 (en) * 2018-10-15 2020-04-23 Tempus Labs, Inc. Microsatellite instability determination system and related methods
CN111321221B (zh) * 2018-12-14 2022-09-23 中国医学科学院肿瘤医院 用于预测直肠癌局部切除手术后复发风险的组合物、微阵列和计算机系统
CN114480632B (zh) * 2020-11-16 2023-05-16 江萤 人微卫星不稳定位点的检测方法及其应用
CN112708679B (zh) * 2021-01-27 2023-01-24 厦门艾德生物医药科技股份有限公司 检测人群微卫星不稳定性的生物标志物组及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020058265A1 (en) * 2000-09-15 2002-05-16 Promega Corporation Detection of microsatellite instability and its use in diagnosis of tumors
US10262103B2 (en) * 2008-11-18 2019-04-16 Raphael LEHRER Individualized cancer treatment

Also Published As

Publication number Publication date
EP2686450A4 (en) 2014-09-10
WO2012129092A1 (en) 2012-09-27
TW201300777A (zh) 2013-01-01
CA2830416A1 (en) 2012-09-27
EP2686450A1 (en) 2014-01-22
US20120238464A1 (en) 2012-09-20

Similar Documents

Publication Publication Date Title
AR085440A1 (es) Biomarcadores para predecir la recurrencia de metastasis de cancer colorrectal
CL2023000812A1 (es) Péptidos, combinaciones y andamiajes para uso en inmunoterapia contra el cáncer divisional de solic.2017-02448
CY1123823T1 (el) Βελτιωμενες συνθεσεις τ κυτταρων
EA201992001A1 (ru) Композиции и способы повышения экспрессии генов
EP3683321A3 (en) Methods relating to circulating tumor cell clusters and the treatment of cancer
BR112018001683A2 (pt) adenovírus recombinante, composição, uso de um adenovírus ou uma composição, e, adenovírus de símio não humano.
PH12016500331A1 (en) Survival benefit in patients with solid tumors with elevated c-reactive protein levels
CY1123856T1 (el) Αντικαρκινικες συνθεσεις
BR112017011172A2 (pt) atenuação de interferência para sinais de referência de posicionamento
CL2017003456A1 (es) Metodos para tratar tumores de celulas epitelioides
EA201691866A1 (ru) Проникающие в опухоль лимфоциты для адоптивной клеточной терапии
AR105602A1 (es) Medio de cultivo celular suplementado con taurina y métodos de utilización
BR112015030627A2 (pt) marcadores biológicos úteis na imunoterapia contra o câncer
UY34844A (es) Formas sólidas de un compuesto antiviral
GB2526736A (en) Methods, compositions, and kits for nucleic acid analysis
EA201400984A2 (ru) Способы и аппараты для прогнозирования риска рака предстательной железы и объема предстательной железы
EA201201000A1 (ru) Способы лечения колоректального рака
EA201391523A1 (ru) Композиции и способы для переноса энергии митохондрий аутологичных герминативных клеток
AR093446A1 (es) Anticuerpos de antihemaglutinina y metodos de uso
CL2012002904A1 (es) Combinación o composición farmacéutica que comprende un inhibidor de la señalización de células y/o de la angiogénesis y un inhibidor de la quinasa aurora (aki); kit faramcéutico que la comprende; su uso en el tratamiento de enfermedades oncológicas y fibróticas; y compuestos derivados de indol y pirimidina sustituidos.
BRPI0607676A2 (pt) anticorpos contra isoformas de cspcna e usos destes
AR099037A1 (es) Aparato y método para la generación de una pluralidad de canales de audio
CL2017001487A1 (es) Uso de los inhibidores de pan fgfr y método para identificación de pacientes con cáncer elegibles para el tratamiento con un inhibidor de pan fgfr.
MX2017010122A (es) Composiciones y metodos para determinar el pronostico de cancer de endometrio.
CY1119468T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιεχουν αλισποριβιρη

Legal Events

Date Code Title Description
FB Suspension of granting procedure